Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice

Rojas, Patricia; Ruiz-Sánchez, Elizabeth; Rojas, Carolina; Ögren, Sven Ove

doi:10.1016/j.neuroscience.2012.08.004

Cited by 38 publications

(16 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…EGb 761, extracted from Ginkgo biloba leaves, has been applied in clinical trials of treating several neuropsychiatric diseases [74,75]. It also exerts neuroprotective effect in MPTP-lesioned mice via increasing the expression of a series of DA-related genes, of which Nurr1 is increased by 148% in SN [71]. Our previous study has shown that radicicol could induce HSP70 expression in SH-SY5Ycells against rotenone-induced apoptosis through the inhibition of P53 and induction of Nurr1 [72].…”

Section: Nurr1 Modulatorsmentioning

confidence: 99%

Nurr1‐Based Therapies for Parkinson's Disease

Dong

et al. 2016

CNS Neurosci Ther

104

View full text Add to dashboard Cite

Previous studies have documented that orphan nuclear receptor Nurr1 (also known as NR4A2) plays important roles in the midbrain dopamine (DA) neuron development, differentiation and survival. Furthermore, it has been reported that the defects in Nurr1 are associated with Parkinson’s disease (PD). Thus, Nurr1 might be a potential therapeutic target for PD. Emerging evidence from in vitro and in vivo studies has recently demonstrated that Nurr1-activating compounds and Nurr1 gene therapy are able not only to enhance DA neurotransmission but also to protect DA neurons from cell injury induced by environmental toxin or microglia-mediated neuroinflammation. Moreover, modulators that interact with Nurr1 or regulate its function, such as retinoid X receptor, cyclic AMP-responsive element-binding protein, glial cell line-derived neurotrophic factor and Wnt/β-catenin pathway have the potential to enhance the effects of Nurr1-based therapies in PD. This review highlights the recent progress in preclinical studies of Nurr1-based therapies and discusses the outlook of this emerging therapy as a promising new generation of PD medication.

show abstract

Section: Nurr1 Modulatorsmentioning

confidence: 99%

Nurr1‐Based Therapies for Parkinson's Disease

Dong

et al. 2016

CNS Neurosci Ther

104

View full text Add to dashboard Cite

show abstract

“…The toxicological and pharmacological properties of EGb761 are well - characterized. A number of preclinical studies have suggested neuroprotective effects for EGb7612122, and it have been widely used in prevention and treatment of Alzheimer’s disease and dementia in elder individuals23. The molecular mechanisms of neuroprotective effects of EGb761 are of multiple-aspects, including anti-apoptosis, anti-inflammatory, protecting mitochondria24, etc.…”

mentioning

confidence: 99%

Ginkgo biloba extract EGb761 attenuates brain death-induced renal injury by inhibiting pro-inflammatory cytokines and the SAPK and JAK-STAT signalings

Xiong

Zhang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

This study aimed to investigate the protective effects of EGb761, a Ginkgo Biloba extract, against brain death-induced kidney injury. Sixty male Sprague Dawley rats were randomly divided into six groups: sham, brain-death (BD), BD + EGb b48h (48 hours before BD), BD + EGb 2 h (2 hours after BD), BD + EGb 1 h, and BD + EGb 0.5 h. Six hours after BD, serum sample and kidney tissues were collected for analyses. The levels of blood urea nitrogen (BUN) and serum creatinine significantly elevated in the BD group than in sham group. In all the EGb761-treated BD animals except for the BD + Gb 2 h group, the levels of BUN and serum creatinine significantly reduced (all P < 0.01). EGb761 attenuated tubular injury and lowered the histological score. In addition, the longer duration of drug treatment was, the better protective efficacy could be observed. EGb761 significantly reduced IL-1β, IL-6, TNF-α, MCP-1, IP-10 mRNA expression and macrophage infiltration in the kidney. EGb761 treatment at 48 hour before brain death significantly attenuate the levels of p-JNK-MAPK, p-p38-MAPK, and p-STAT3 proteins (all P < 0.05, compared to BD group). In summary, our data showed that EGb761 treatment protected donor kidney from BD-induced damages by blocking SAPK and JAK-STAT signalings. Early administration of EGb761 can provide better protective efficacy.

show abstract

“…Taken together our results are compatible with an EGb 761®-induced mild prefrontal dopaminergic enhancement. Recent reports from animal models of dopamine sensitive learning (Moeller et al, 2009), sexual function (Yeh et al, 2011) and Parkinson's disease (Rojas et al, 2012) as well as clinical findings in ADHD (Klement et al, 2011), tardive dyskinesia (Zhang et al, 2011) and negative symptoms in schizophrenia (Doruk et al, 2008) contribute to the hypothesis of mild prefrontal dopaminergic action of this specific ginkgo extract. Dopaminergic effects in the PFC could be explained by mild inhibition of the norepinephrine transporter that has been reported for ginkgo flavone glycosides (Fehske et al, 2009).…”

Section: Discussionmentioning

confidence: 98%

Effects of Ginkgo biloba extract EGb 761® on cognitive control functions, mental activity of the prefrontal cortex and stress reactivity in elderly adults with subjective memory impairment – a randomized double‐blind placebo‐controlled trial

Beck

Ruge

Schindler

et al. 2016

Human Psychopharmacology

View full text Add to dashboard Cite

ObjectiveCognitive control as well as stress reactivity is assumed to depend on prefrontal dopamine and decline with age. Because Ginkgo biloba extract EGb761® increases prefrontal dopamine in animals, we assessed its effects on cognitive functions related to prefrontal dopamine.MethodsEffects of 240‐mg EGb761® daily on task‐set‐switching, response‐inhibition, delayed response, prospective‐memory, task‐related fMRI‐BOLD‐signals and the Trier Social Stress‐Test were explored in a randomized, placebo‐controlled, double‐blind pilot‐trial in 61 elderly volunteers with subjective memory impairment.† ResultsBaseline‐fMRI‐data showed BOLD‐responses in regions commonly activated by the specific tasks. Task‐switch‐costs decreased with EGb761® compared to placebo (ANOVA‐interaction: Group × Time × Switch‐Costs p = 0.018, multiple tests uncorrected), indicating improved cognitive flexibility. Go–NoGo‐task reaction‐times corrected for error‐rates indicated a trend for improved response inhibition. No treatment effects were found for the delayed response and prospective‐memory tasks and fMRI‐data. A non‐significant trend indicated a potentially accelerated endocrine stress‐recovery. EGb761® was safe and well tolerated.ConclusionWe observed indications for improved cognitive flexibility without changes in brain activation, suggesting increased processing efficiency with EGb761®. Together with a trend for improved response inhibition results are compatible with mild enhancement of prefrontal dopamine. These conclusions on potential beneficial effect of EGb761® on prefrontal dopaminergic functions should be confirmed by direct measurements. © 2016 The Authors. Human Psychopharmacology: Clinical and Experimental published by John Wiley & Sons, Ltd.

show abstract

Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice

Cited by 38 publications

References 67 publications

Nurr1‐Based Therapies for Parkinson's Disease

Nurr1‐Based Therapies for Parkinson's Disease

Ginkgo biloba extract EGb761 attenuates brain death-induced renal injury by inhibiting pro-inflammatory cytokines and the SAPK and JAK-STAT signalings

Effects of Ginkgo biloba extract EGb 761® on cognitive control functions, mental activity of the prefrontal cortex and stress reactivity in elderly adults with subjective memory impairment – a randomized double‐blind placebo‐controlled trial

Contact Info

Product

Resources

About